HKSE - Delayed Quote HKD

TOT BIOPHARM-B (1875.HK)

Compare
1.890
0.000
(0.00%)
At close: January 24 at 10:08:57 AM GMT+8
Currency in CNY All numbers in thousands
Download
Breakdown
TTM
12/31/2023
12/31/2022
12/31/2021
12/31/2020
Total Revenue
780,629.000
780,629.000
442,178.000
76,325.000
22,491.000
Cost of Revenue
206,643.000
206,643.000
71,563.000
48,851.000
6,961.000
Gross Profit
573,986.000
573,986.000
370,615.000
27,474.000
15,530.000
Operating Expense
595,433.000
595,433.000
409,449.000
282,928.000
305,268.000
Operating Income
-21,447.000
-21,447.000
-38,834.000
-255,454.000
-289,738.000
Net Non Operating Interest Income Expense
-2,201.000
-2,201.000
-4,337.000
-1,499.000
174.000
Pretax Income
-37,756.000
-37,756.000
-50,046.000
-261,216.000
-288,498.000
Tax Provision
1.000
1.000
--
--
--
Net Income Common Stockholders
-37,757.000
-37,757.000
-49,916.000
-261,216.000
-288,498.000
Diluted NI Available to Com Stockholders
-37,757.000
-37,757.000
-49,916.000
-261,216.000
-288,498.000
Basic EPS
-0.05
--
-0.08
-0.46
-0.51
Diluted EPS
-0.05
--
-0.08
-0.46
-0.51
Basic Average Shares
725,197.000
--
639,307.000
573,360.000
570,334.000
Diluted Average Shares
725,197.000
--
639,307.000
573,360.000
570,334.000
Total Operating Income as Reported
-33,060.000
-33,060.000
-39,076.000
-259,700.000
-288,672.000
Total Expenses
802,076.000
802,076.000
481,012.000
331,779.000
312,229.000
Net Income from Continuing & Discontinued Operation
-37,757.000
-37,757.000
-49,916.000
-261,216.000
-288,498.000
Normalized Income
-27,284.000
-27,284.000
-47,872.000
-255,464.000
-288,846.000
Interest Income
2,974.000
2,974.000
2,265.000
969.000
1,880.000
Interest Expense
5,175.000
5,175.000
6,602.000
2,468.000
1,706.000
Net Interest Income
-2,201.000
-2,201.000
-4,337.000
-1,499.000
174.000
EBIT
-32,581.000
-32,581.000
-43,444.000
-258,748.000
-286,792.000
EBITDA
10,447.000
10,447.000
-5,405.000
-224,511.000
-254,710.000
Reconciled Cost of Revenue
206,643.000
206,643.000
71,563.000
48,851.000
6,961.000
Reconciled Depreciation
43,028.000
43,028.000
38,039.000
34,237.000
32,082.000
Net Income from Continuing Operation Net Minority Interest
-37,757.000
-37,757.000
-49,916.000
-261,216.000
-288,498.000
Total Unusual Items Excluding Goodwill
-13,964.000
-13,964.000
-2,044.000
-5,752.000
348.000
Total Unusual Items
-13,964.000
-13,964.000
-2,044.000
-5,752.000
348.000
Normalized EBITDA
24,411.000
24,411.000
-3,361.000
-218,759.000
-255,058.000
Tax Rate for Calcs
0.000
0.000
--
--
--
Tax Effect of Unusual Items
-3,491.000
-3,491.000
--
--
--
12/31/2020 - 11/8/2019

Upgrade to begin using 40 years of financial statements and get so much more.

Perform in-depth fundamental analysis with decades of income statements, balance sheets, and cash flows — all exportable.

Upgrade

Related Tickers

7754.TWO AnnJi
32.55
0.00%
 
2696.HK Shanghai Henlius Biotech, Inc.
16.860
-0.82%
 
7776.TWO Anya
37.35
+0.40%
 
6549.TWO TaiwanJ Pharmaceuticals Co., Ltd.
8.50
+2.04%
 
4192.TWO SynCore Biotechnology Co.,Ltd
34.85
+2.20%
 
6696.TWO Lin BioScience, Inc.
152.00
+4.47%
 
6733.TWO BioGend Therapeutics Co., Ltd.
32.80
-0.30%
 
4726.TWO Mycenax Biotech Inc.
39.65
+0.38%
 
6838.TW Formosa Pharmaceuticals, Inc.
34.75
+2.06%
 
GMAB Genmab A/S
20.80
-1.56%